Assessment of the antidiabetic and antilipidemic properties of bacillus subtilis spb1 biosurfactant in alloxan‐induced diabetic rats

Abstract

The present study aimed to scrutinize the potential of Bacillus subtilis SPB1biosurfactant, orally administered, for preventing diabetic complications in rats. The findings revealed that, Bacillus subtilis biosurfactant was an effective reducer of α-amylase activity in the plasma. Moreover, this supplement helped protect the β-cells from death and damage. Both the inhibitory action of SPB1 biosurfactant on α-amylase and the protection of the pancreas' β-cells lead to a decrease of the blood glucose levels, consequently antihyperglycemic effect. Interestingly, this lipopeptide biosurfactant modulated key enzyme related to hyperlipidemia as lipase; which leads to the regulation of the lipid profile in serum by the delay in the absorption of LDL-cholesterol and triglycerides, and a significant increase in HDL-cholesterol. Histological analyses also showed that it exerted a protective action on the pancreases and efficiently preserved the liver-kidney functions of diabetic rats, evidenced by significant decreases in aspartate transaminase, alanine transaminase, gamma-glytamyl transpeptidase and lactate deshydrogenase activities in the plasma, as well as in the creatinine and urea contents. Overall, the present study demonstrated that the hypoglycemic and antilipidemic activities exhibited by Bacillus subtilis biosurfactant were effective enough to alleviate induced diabetes in experimental rats. Therefore, SPB1biosurfactant could be considered as a potential strong candidate for the treatment and prevention of diabetes.

In vitro and in vivo antimicrobial activity of Ulva lactuca Linn. (Green algae) associated endophytic bacterial Strains

“…Novel secondary metabolites like lipopeptides, Oxylipins, Limnazine, beta-1,3-1, 4-glucanase are reported from bacillus Sps. (Gond et al, 2015, Trapp et al, 2015, Chen et al, 2013, Asolkar et al, 2002, Zouari et al, 2015, Jin et al, 2011, Liu et al, 2009. Enterobacter cloacae.…”

Bacillus As Potential Probiotics: Status, Concerns, and Future Perspectives

“…In this study, the therapeutic effect of EPS was recorded due to reduced blood glucose, troponin, total serum cholesterol, LDL, and VLDL as well as suppression of ICAM and VCAM expression. Earlier, Zouari et al (2015) also explored the anti-diabetic and anti-lipidemic properties of biosurfactant produced by B. subtilis SPB1 strain in alloxan induced diabetic rats. Upon oral administration, the biosurfactant reduced the plasma alpha-amylase activity and rendered protection to pancreatic beta cells.…”

Comparative study of antidiabetic, bactericidal, and antitumor activities of MEL@AgNPs, MEL@ZnONPs, and Ag–ZnO/MEL/GA nanocomposites prepared by using MEL and gum arabic

“…In diabetic group, lipid droplets were observed in the cytoplasm of hepatic and renal tissues, due to the lack of insulin responsible for metabolizing fats. 61 The chemical surfactants are usually used to enhance the solubility and delivery of antidiabetic drugs such as SDS, CTAB and Tween-80. 62 Also, Edwards and his colleagues 63 suggested that using different kind of gums could be effective in reducing postprandial hyperglycemia in human.…”